Dr Michael Morrison
Principal Investigator Biomodifying Technologies, HeLEX
Michael has an MA (by Research and Thesis) and PhD from the interdisciplinary Institute for Science and Society (ISS) at the University of Nottingham. He also holds a BSc in Biology from the University of St. Andrews (2000). Michael has previously worked on the IMI STEMBANCC project, providing governance and ethical support to the project. He has also been a researcher on the Framework Programme 7 Regenerative Medicine in Europe (REMEDiE) project at the University of York and with the Health Technology and Society group at the University of Exeter.
Michael’s primary research interest and expertise lies in the application of insights and perspectives from Science and Technology Studies (STS) and medical sociology to the study of novel and emerging biotechnologies. More specifically, he is concerned with understanding the ways in which these technologies are shaped by a variety of social factors – including institutional and regulatory cultures as well as the perspectives of developers and prospective users – throughout the course of their development and deployment into practice; and how, in turn, new biomedical technologies shape and reconfigure our understandings of disease, health, and the ‘sorts’ of people we are or can be. He is also working with Jane Kaye and other HeLEX members to develop novel consent procedures for large-scale biobanking projects.
Tensions in ethics and policy created by National Precision Medicine Programs.
Minari J. et al, (2018), Hum Genomics, 12
Including all voices in international data-sharing governance.
Kaye J. et al, (2018), Hum Genomics, 12
Regulating human stem cell research and therapy in low- and middle-income countries: Malaysian perspectives
Bin Abdul Aziz MF. et al, (2017), New Genetics and Society, 1 - 19
"A good collaboration is based on unique contributions from each side": assessing the dynamics of collaboration in stem cell science.
Morrison M., (2017), Life Sci Soc Policy, 13
Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic.
Nicol D. et al, (2017), Genome Med, 9